Influenza viruses cause costly recurrent annual epidemics. Current efforts to control the
morbidity and mortality associated with influenza outbreaks are based on the use of annual
intramuscularly administered inactivated vaccines which are not only painful to administer,
but are suboptimal in efficacy. This paper reviews the composition, safety analysis, rates of
adverse events, immune response and protective efficacy of a new inactivated intranasal
influenza vaccine.